{"id":18602,"date":"2021-02-03T15:03:59","date_gmt":"2021-02-03T13:03:59","guid":{"rendered":"https:\/\/vilkaviskiovsb.lt\/?p=18602"},"modified":"2021-02-03T15:03:59","modified_gmt":"2021-02-03T13:03:59","slug":"lietuva-ketina-isigyti-covid-19-vakcinu-is-dar-dvieju-gamintoju","status":"publish","type":"post","link":"https:\/\/vilkaviskiovsb.lt\/en\/2021\/02\/03\/lietuva-ketina-isigyti-covid-19-vakcinu-is-dar-dvieju-gamintoju\/","title":{"rendered":"Lietuva ketina \u012fsigyti COVID-19 vakcin\u0173 i\u0161 dar dviej\u0173 gamintoj\u0173"},"content":{"rendered":"<p><strong>Siekdama paspartinti vakcin\u0173 tiekim\u0105 ir gyventoj\u0173 vakcinacij\u0105 nuo koronaviruso (COVID-19), Vyriausyb\u0117 tre\u010diadien\u012f pritar\u0117 vakcin\u0173 \u012fsigijimui i\u0161 dar dviej\u0173 farmacijos kompanij\u0173: \u201eNovavax\u201c ir \u201eValneva\u201c. Pirmasis gamintojas prad\u0117ti tiekim\u0105 gal\u0117t\u0173 jau antr\u0105j\u012f \u0161i\u0173 met\u0173 ketvirt\u012f.<\/strong><\/p>\n<p>Ruo\u0161iantis prad\u0117ti oficialias derybas su \u201eNovavax\u201c ir \u201eValneva\u201c, Europos Komisija apklausia valstybes nares d\u0117l numatom\u0173 \u012fsigyti vakcin\u0173 kiekio. Vadovaujantis proporcingumo kriterijumi, Lietuvos Vyriausyb\u0117 pritar\u0117 si\u016blymui \u012fsigyti 620 t\u016bkst. \u201eNovavax\u201c ir 186 t\u016bkst. \u201eValneva\u201c vakcinos dozi\u0173, jei bus sudaromos i\u0161ankstin\u0117s pirkimo sutartys. Ar bus pasira\u0161ytos preliminarios pirkimo sutartys, paai\u0161k\u0117s pasibaigus deryboms.<\/p>\n<p>Abi kompanijos \u0161iuo metu atlieka vakcin\u0173 klinikinius tyrimus, kuriuose dalyvauja t\u016bkstan\u010diai savanori\u0173. S\u0117kmingai u\u017ebaigus \u0161iuos tyrimus, gamintojai teiks parai\u0161kas vakcin\u0173 registravimui Europos S\u0105jungoje. Registracij\u0105 tvirtins Europos Komisija, atsi\u017evelgdama \u012f Europos vaist\u0173 agent\u016bros i\u0161vadas.<\/p>\n<p>Europos S\u0105jungoje \u0161iuo metu yra u\u017eregistruotos trij\u0173 gamintoj\u0173 vakcinos: \u201eBioNTech &amp; Pfizer\u201c, \u201eModerna\u201c ir \u201eAstraZeneca\u201c. I\u0161ankstin\u0117s sutartys taip pat yra sudarytos su gamintojais \u201eJanssen Pharmaceutica NV\u201c, \u201eSanofi Pasteur &amp; GSK\u201c ir \u201eCureVac\u201c.<\/p>\n<p>Pagal i\u0161ankstines sutartis Lietuva jau yra u\u017esisakiusi daugiau nei 9 mln. vakcinos dozi\u0173. \u0160io kieko tur\u0117t\u0173 u\u017etekti paskiepyti daugiau nei 70 proc. \u0161alies gyventoj\u0173. Pasak specialist\u0173, tokia paskiept\u0173 gyventoj\u0173 dalis u\u017etikrint\u0173 kolektyvin\u012f imunitet\u0105 nuo koronaviruso.<\/p>\n<p>Vakcinacija Lietuvoje vykdoma pagal Sveikatos apsaugos ministerijos patvirtint\u0105 plan\u0105. J\u012f ir kit\u0105 aktuali\u0105 informacij\u0105 apie vakcinacij\u0105 rasite \u010dia: <a href=\"https:\/\/koronastop.lrv.lt\/lt\/vakcinavimas\" target=\"_blank\" rel=\"noopener\">https:\/\/koronastop.lrv.lt\/lt\/vakcinavimas<\/a><\/p>\n<p><em>SAM Spaudos tarnyba<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Siekdama paspartinti vakcin\u0173 tiekim\u0105 ir gyventoj\u0173 vakcinacij\u0105 nuo koronaviruso (COVID-19), Vyriausyb\u0117 tre\u010diadien\u012f pritar\u0117 vakcin\u0173 \u012fsigijimui i\u0161 dar dviej\u0173 farmacijos kompanij\u0173: \u201eNovavax\u201c ir \u201eValneva\u201c. Pirmasis gamintojas prad\u0117ti tiekim\u0105 gal\u0117t\u0173 jau antr\u0105j\u012f \u0161i\u0173 met\u0173 ketvirt\u012f. Ruo\u0161iantis prad\u0117ti oficialias derybas su \u201eNovavax\u201c ir \u201eValneva\u201c, Europos Komisija apklausia valstybes nares d\u0117l numatom\u0173 \u012fsigyti vakcin\u0173 kiekio. Vadovaujantis proporcingumo kriterijumi, Lietuvos&hellip;<\/p>","protected":false},"author":3,"featured_media":18603,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[100],"tags":[],"class_list":["post-18602","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-del-covid-19","category-100","description-off"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7kWFe-4Q2","jetpack_featured_media_url":"https:\/\/vilkaviskiovsb.lt\/wp-content\/uploads\/2021\/02\/18683_4092065a76a457bbf94cf18f10da7575.jpg","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/18602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/comments?post=18602"}],"version-history":[{"count":1,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/18602\/revisions"}],"predecessor-version":[{"id":18604,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/18602\/revisions\/18604"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/media\/18603"}],"wp:attachment":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/media?parent=18602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/categories?post=18602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/tags?post=18602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}